Blood pressure control, proteinuria and renal outcome in chronic renal failure

Current Opinion in Nephrology and Hypertension

Volumn 7, Issue 2, 1998, Pages 145-148

  Ruilope, Luis M ^a   Campo, Carlos ^a   Rodicio, Jose L ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; VERAPAMIL;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HYPERTENSION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; PROTEINURIA;

EID: 0031882721     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199803000-00001     Document Type: Review

References (28)

1. Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney Int 1989; 35:670-674.
2. William JD, Coles GA. Proteinuria - a direct cause of renal morbidity? Kidney Int 1994; 45:443-450.
3. Williams PS, Fass G, Bone JM. Renal pathology and proteinuria determine progression in untreated mild moderate chronic renal failure. Q J Med 1988; 67:343-354.
4. Baldwin DS, Neugarten J. Blood pressure control and progression of renal insufficiency. Contemp Issues Nephrol 1986; 14:81-110.
5. Birkenhager WH, Schalekamp MADH. Renal hemodynamics and renal function. In: Control mechanisms in essential hypertension. Birkenhager WH, Schalekamp MADH (editors). Amsterdam: Elsevier; 1976. pp. 43-63.
6. Brenner BM. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 1983; 23:647-655.
7. Perera GA. Hypertensive vascular disease: description and natural history. J Chron Dis 1955; 1:33-42.
8. Cameron JS, Turner DR, Ogg CS, Chantler C, Williams DG. The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 1978; 10:213-218.
9. Cameron JS, Turner DR, Heaton J, Williams G, Ogg CS, Chantier C, et al. Idiopathic mesangiocapillary glomerulonephritis: comparison of types I and II in children and adults and long-term prognosis. Am J Med 1983; 74:175-192.
10. Erwin DT, Donadio DSV, Holley KE. The clinical course of idiopathic membranous nephropathy. Mayo Clin Proc 1973; 48:697-712.
11. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330:877-884.
12. Praga M, Hernandez E, Montoyo C, Andres A, Ruilope LM, Rodicio JL. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1994; 20:240-248.
13. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 1994; 45 (suppl):145-149.
14. The Gisen Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349:1857-1863. This study shows that the percentage reduction in proteinuria obtained with ramipril was inversely correlated with the decline in glomerular filtration rate. The reduction in the renal risk was significantly reduced after adjustment for changes in systolic and diastolic blood pressure.
15. Burton C, Harris KPG. The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 1996; 27:765-775. An excellent review of the mechanisms through which proteinuria accelerates the progression of chronic renal failure.
16. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51:2-15. In this article the authors make a comprehensive review of the factors facilitating the progression of renal insufficiency, with particular emphasis on proteinuria and blood pressure control.
17. Risdon RA, Sloper JC, de Wardener HE. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1966; 2:363-366.
18. Schainuk LI, Striker GE, Cutler RE, Benditt EP. Structural functional correlations in renal disease. Part II: The correlations. Hum Pathol 1970; 1:631-641.
19. Parving HH, Jensen HAE, Mogensen CE, Evrin PE. Increased urinary albumin excretion rate in benign essential hypertension. Lancet 1974; 1:1190-1192.
20. Gansevoort RT, Sluiter WJ, Hemmelder MH, De Zeeuw D, De Jong PE. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10:1963-1974.
21. Gansevoort RT, De Zeeuw D, De Jong PE. Is the antiproteinuric effect of ACE inhibition mediatd by interference in the renin-angiotensin system? Kidney Int 1994; 45:861-867.
22. Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated metaanalysis. Nephrol Dial Transplant 1995; 10 (suppl 9):39-45.
23. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. for the Modification of Diet in Renal Disease (MDRD) Study Group. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123:754-762.
24. Hebert LE, Kusek JW, Greene T, Agodoa LY, Jones CA, Levey AS, et al. for the Modification of Diet in Renal Disease Study Group. Writing Group. Effects of blood pressure control on progressive renal disease in blacks and whites. Hypertension 1997; 30 (part 1):428-435. This paper contains a secondary analysis of the MDRD Study and supports the previous recommendations for a lower than usual blood pressure goal in black and white patients with proteinuria greater than 1 g per day.
25. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-1462.
26. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, et al. Ace inhibition in progressive renal insufficiency study group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334:939-945.
27. Hansson L, Zanchetti A for the HOT Study Group. The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Pressure 1997; 6:313-317. In this article the therapeutic requirements necessary to obtain an adequate control of blood pressure are presented. The need for combination therapy in patients when the expected goal of diastolic blood pressure is lower than 90mmHg was attained by more than 70% of the patients.
28. Tarif N, Bakris GL. Preservation of renal function; the spectrum of effects by calcium channel blockers. Nephrol Dial Transplant 1997; 12:2244-2250. The authors make a complete review of the long-term clinical studies that have evaluated the progression of renal disease with the various calcium antagonists.